Big data vs. big trials: can claims records match Gold-Standard results?
NCT ID NCT07599345
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study uses healthcare claims data from nearly 24,000 people to see if it can reproduce the results of the EMPEROR-Reduced trial, which tested the diabetes drug empagliflozin against sitagliptin in heart failure patients. The goal is not to test a new treatment, but to learn whether real-world data can reliably mimic clinical trials. If it works, it could pave the way for faster, cheaper research using existing health records.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin and sitagliptin
What this could lead to
If successful, this could show that analyzing real-world data can reliably reproduce results from expensive clinical trials, making future research faster and cheaper.
What could go wrong
This is an observational study, not a controlled experiment, so results may be biased or not match the original trial. It only looks at existing records, not new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States